PT-141 for Male ED: What the Clinical Data Shows
Bremelanotide and Sexual Dysfunction
34% response rate
In a placebo-controlled trial of 342 men with ED who had failed sildenafil, 34% of those receiving PT-141 reported improved erections, compared to 9% on placebo.
Safarinejad et al., 2008
Safarinejad et al., 2008
View as imagePT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that produces erections through a mechanism fundamentally different from Viagra and related PDE5 inhibitors. While PDE5 inhibitors work locally by increasing blood flow to the penis, PT-141 acts centrally through melanocortin receptors (MC3R and MC4R) in the hypothalamus, activating the neural pathways that initiate sexual arousal and the erectile response. The FDA approved bremelanotide in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It has never been approved for male erectile dysfunction. But the clinical data for male ED exists: multiple placebo-controlled trials tested PT-141 in men, including men who had failed PDE5 inhibitors, and the results showed statistically significant improvements in erectile function. For background on how this peptide was discovered and approved, see Vyleesi for Women: The Clinical Evidence on Hypoactive Sexual Desire.
Key Takeaways
- PT-141 produces erections by activating MC3R and MC4R in the hypothalamus, triggering descending neural signals rather than directly increasing penile blood flow[5]
- In a placebo-controlled trial of 342 sildenafil non-responders, 34% of men receiving intranasal PT-141 (10 mg) reported improved erectile function versus 9% on placebo[7]
- Co-administration of PT-141 (7.5 mg intranasal) with low-dose sildenafil (25 mg) produced significantly greater erectile response than sildenafil alone, suggesting a synergistic effect from targeting both central and peripheral pathways[4]
- The erectile response to PT-141 was dose-dependent in early clinical studies, with onset in approximately 30 minutes and duration of several hours[2]
- PT-141 increased subjective sexual desire alongside erectile function, a dual effect that PDE5 inhibitors do not produce[1]
- The drug is not approved for male ED and all clinical data comes from Phase 2 studies; no Phase 3 male ED trial has been completed
The Accidental Discovery: From Tanning Peptide to Erection
The story of PT-141 begins with melanotan II, a synthetic melanocortin peptide originally developed to produce sunless tanning. During clinical testing in the mid-1990s, researchers noticed an unexpected side effect: male subjects developed spontaneous erections. Wessells and colleagues published the first formal report in 2000, documenting that melanocortin receptor agonists produced penile erection and increased sexual motivation in human males.[9]
This was not a vascular phenomenon. The erections occurred through a central nervous system mechanism. Melanotan II activated melanocortin receptors (MC3R and MC4R) in the hypothalamus, which sent descending signals through the spinal cord to the sacral parasympathetic outflow, ultimately triggering erection. Hadley (2005) published a review documenting the scientific path from this accidental discovery to the development of PT-141 as a dedicated sexual function drug.[5]
PT-141 (bremelanotide) is a cyclic heptapeptide, a modified metabolite of melanotan II. It was engineered to retain the sexual function effects while reducing the tanning and other melanocortin-mediated side effects. The key modification: PT-141 has reduced MC1R activity (the tanning receptor) compared to melanotan II, while preserving MC3R and MC4R activity (the receptors responsible for sexual arousal).
How PT-141 Differs from Viagra
The mechanistic difference between PT-141 and PDE5 inhibitors is fundamental, not incremental. See How Bremelanotide Works: A Central Nervous System Approach to Desire for a detailed explanation.
PDE5 inhibitors (sildenafil, tadalafil, vardenafil) work peripherally. They inhibit the enzyme phosphodiesterase type 5 in penile smooth muscle, allowing cyclic GMP to accumulate and relax the smooth muscle, increasing blood flow. They require sexual stimulation to produce an erection because they amplify an existing signal. They do not affect sexual desire.
PT-141 works centrally. It activates melanocortin receptors in the hypothalamus, initiating the neural cascade that produces both sexual desire and the erectile response from the top down. Wessells (2005) published a detailed review of the melanocortinergic control of penile erection, mapping the pathway from hypothalamic MC4R activation through the paraventricular nucleus to the spinal erectile centers.[6]
This mechanistic difference has a critical clinical implication: PT-141 can work in men who do not respond to PDE5 inhibitors. If the problem is upstream (lack of neural drive, diminished desire) rather than downstream (insufficient blood flow), a drug that acts on the brain addresses the root cause while a drug that acts on blood vessels does not.
Clinical Evidence in Men
Early dose-finding studies
Molinoff and colleagues published the first overview of PT-141 as a melanocortin agonist for sexual dysfunction in 2003, summarizing preclinical and early clinical data showing dose-dependent erectile responses in men.[1]
Diamond and colleagues (2004) conducted a double-blind, placebo-controlled study evaluating intranasal PT-141 in healthy males and men with mild-to-moderate ED. They found a dose-dependent increase in erectile activity measured by RigiScan (a penile rigidity monitoring device), with onset approximately 30 minutes after dosing. The intranasal route achieved measurable systemic absorption and pharmacodynamic effects.[2]
Rosen and colleagues (2004) evaluated subcutaneous PT-141 in men with ED who had previously responded to sildenafil. In a laboratory setting with visual sexual stimulation, subcutaneous PT-141 enhanced erectile response in a dose-dependent manner. The study also noted that PT-141 increased subjective sexual desire, an effect not seen with PDE5 inhibitors.[3]
The sildenafil non-responder trial
The most clinically meaningful data came from Safarinejad (2008), published as "Salvage of sildenafil failures with bremelanotide" in the Journal of Urology. This was a randomized, double-blind, placebo-controlled trial enrolling 342 men with ED who had not responded to sildenafil. Patients received either intranasal PT-141 (10 mg) or placebo before sexual activity. In the PT-141 group, 34% reported significantly improved erectile function, compared to 9% on placebo (p < 0.001). The response was assessed using the International Index of Erectile Function (IIEF) erectile function domain score.[7]
This trial matters because it tested PT-141 in the population that needs it most: men for whom existing treatments have failed. A 34% response rate in PDE5 non-responders demonstrates that targeting the central melanocortin pathway can rescue erectile function even when the peripheral vascular pathway is insufficient.
Combination with PDE5 inhibitors
Diamond and colleagues (2005) tested co-administration of low-dose intranasal PT-141 (7.5 mg) with low-dose sildenafil (25 mg) in men with ED. The combination produced a significantly greater erectile response than sildenafil alone. Both drugs were well tolerated together, with no adverse pharmacodynamic interaction.[4]
This finding is pharmacologically logical: combining a central arousal enhancer with a peripheral blood flow enhancer should produce additive or synergistic effects because they target non-overlapping parts of the erectile pathway.
Broader Melanocortin Research
Shadiack and colleagues (2007) reviewed the broader landscape of melanocortins in treating both male and female sexual dysfunction, noting that the melanocortin system represents the only known central nervous system pathway with direct, pharmacologically accessible control over human sexual function.[10]
Uckert and colleagues (2014) published an updated review of melanocortin receptor agonists for sexual dysfunction, incorporating a decade of clinical results. They noted that while the male ED data was consistently positive across multiple trials, the development program shifted focus to female HSDD because of the larger unmet clinical need and the absence of any approved pharmacological treatment for that condition at the time.[8]
Pfaus and colleagues (2022) published a comprehensive review of bremelanotide's neurobiology in Pharmacology & Therapeutics, detailing how MC4R activation in the medial preoptic area and paraventricular nucleus activates descending oxytocin and dopaminergic pathways that coordinate both desire and physiological arousal.[11]
Why PT-141 Is Not Approved for Male ED
Despite consistently positive clinical data, PT-141 was never submitted for FDA approval for male erectile dysfunction. Several factors explain this.
The regulatory pathway for male ED is crowded and well-established. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are effective in 60-70% of men, are available as oral pills, and several are now generic. A subcutaneous injection (the final dosing form for bremelanotide) faces a high bar for adoption in a market where oral alternatives exist.
The intranasal formulation, which was tested in male ED trials, was abandoned due to concerns about blood pressure elevation. PT-141 can cause transient increases in blood pressure, a side effect that is more concerning in the male ED population (which overlaps heavily with cardiovascular disease) than in the premenopausal HSDD population.
The development company (Palatin Technologies) made a strategic decision to pursue the female HSDD indication, where no pharmacological competition existed. Vyleesi was approved for that indication in 2019.
Limitations of the Evidence
All of the male ED data for PT-141 comes from Phase 2 studies. No Phase 3 male ED trial has been completed. The largest controlled trial (Safarinejad 2008, n=342) was a single study. The long-term safety profile in men with ED has not been established. The blood pressure elevation effect may limit its use in men with cardiovascular comorbidities, which is common in the ED population. Fuentes-Mendoza and colleagues (2026) reviewed sexual dysfunction in the context of weight-loss drugs, noting that GLP-1 agonists may affect sexual function and that future research may explore peptide-based sexual function therapies in this population.[12]
For a comparison of these two fundamentally different approaches, see PT-141 vs PDE5 Inhibitors (Viagra): Fundamentally Different Mechanisms.
The Bottom Line
PT-141 (bremelanotide) produces erections through a central nervous system mechanism (MC3R/MC4R activation in the hypothalamus) rather than the peripheral vascular mechanism used by Viagra. Phase 2 trials showed a 34% response rate in men who had failed sildenafil, dose-dependent erectile responses in multiple studies, and synergistic effects when combined with low-dose sildenafil. The drug also increases subjective sexual desire, which PDE5 inhibitors do not. It is FDA-approved only for female HSDD (as Vyleesi) and has never completed Phase 3 male ED trials. Blood pressure elevation and the dominance of oral PDE5 inhibitors in the market contributed to the decision not to pursue male ED approval.